Safety and Effectiveness Study of Remsima® in the Treatment of Inflammatory Bowel Diseases Among Saudi Arabia Patients
An Observational, Prospective Cohort Study to Evaluate the Safety and Effectiveness of Remsima® in the Treatment of Inflammatory Bowel Disease Among Saudi Arabia Patients Diagnosed With Crohn's Disease, Ulcerative Colitis, or Fistulizing CD
Sponsor: Hikma Pharmaceuticals LLC
Listed as NCT03452501, this observational or N/A phase trial focuses on Crohn Disease and Fistulizing Crohn's Disease and remains completed. Sponsored by Hikma Pharmaceuticals LLC, it has been updated 10 times since 2018, reflecting substantial change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
10 versions recorded-
Sep 2024 — Present [monthly]
Completed
-
Jul 2024 — Sep 2024 [monthly]
Completed
-
Mar 2021 — Jul 2024 [monthly]
Completed
Status: Active Not Recruiting → Completed
-
Jan 2021 — Mar 2021 [monthly]
Active Not Recruiting
-
Aug 2020 — Jan 2021 [monthly]
Active Not Recruiting
▶ Show 5 earlier versions
-
Apr 2020 — Aug 2020 [monthly]
Active Not Recruiting
Status: Unknown Status → Active Not Recruiting
-
Mar 2020 — Apr 2020 [monthly]
Unknown Status
Status: Not Yet Recruiting → Unknown Status
-
Jun 2018 — Mar 2020 [monthly]
Not Yet Recruiting
-
Apr 2018 — Jun 2018 [monthly]
Not Yet Recruiting
Phase: NA → None
-
Mar 2018 — Apr 2018 [monthly]
Not Yet Recruiting NA
First recorded
Eligibility Summary
No eligibility information available.
Contact Information
- Hikma Pharmaceuticals LLC
For direct contact, visit the study record on ClinicalTrials.gov .